The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Comparison of Fixed-Dose Weight-Adjusted Unfractionated Heparin and Low-Molecular-Weight Heparin for Acute Treatment of Venous Thromboembolism
Abstract
CONTEXT: When unfractionated heparin is used to treat acute venous thromboembolism, it is usually administered by intravenous infusion with coagulation monitoring, which requires hospitalization. However, subcutaneous administration of fixed-dose, weight-adjusted, unfractionated heparin may be suitable for inpatient and outpatient treatment of venous thromboembolism. OBJECTIVE: To determine if fixed-dose, weight-adjusted, subcutaneous unfractionated heparin is as effective and safe as low-molecular-weight heparin for treatment of venous thromboembolism. DESIGN, SETTING, AND PATIENTS: Randomized, open-label, adjudicator-blinded, noninferiority trial of 708 patients aged 18 years or older with acute venous thromboembolism from 6 university-affiliated clinical centers in Canada and New Zealand conducted from September 1998 through February 2004. Of the randomized patients, 11 were subsequently excluded from the analysis of efficacy and 8 from the analysis of safety. INTERVENTIONS: Unfractionated heparin was administered subcutaneously as an initial dose of 333 U/kg, followed by a fixed dose of 250 U/kg every 12 hours (n = 345). Low-molecular-weight heparin (dalteparin or enoxaparin) was administered subcutaneously at a dose of 100 IU/kg every 12 hours (n = 352). Both treatments could be administered out of hospital and both were overlapped with 3 months of warfarin therapy. MAIN OUTCOME MEASURES: Recurrent venous thromboembolism within 3 months and major bleeding within 10 days of randomization. RESULTS: Recurrent venous thromboembolism occurred in 13 patients in the unfractionated heparin group (3.8%) compared with 12 patients in the low-molecular-weight heparin group (3.4%; absolute difference, 0.4%; 95% confidence interval, -2.6% to 3.3%). Major bleeding during the first 10 days of treatment occurred in 4 patients in the unfractionated heparin group (1.1%) compared with 5 patients in the low-molecular-weight heparin group (1.4%; absolute difference, -0.3%; 95% confidence interval, -2.3% to 1.7%). Treatment was administered entirely out of hospital in 72% of the unfractionated heparin group and 68% of the low-molecular-weight heparin group. CONCLUSION: Fixed-dose subcutaneous unfractionated heparin is as effective and safe as low-molecular-weight heparin in patients with acute venous thromboembolism and is suitable for outpatient treatment. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00182403.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lee, A. Y. Y., Levine, M. N., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M., Rickles, F. R., Julian, J. A., Haley, S., Kovacs, M. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025313 · Cited by 2,534
Self-citationAntithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., & Weg, J. G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,042
Antithrombotic Therapy for Venous Thromboembolic Disease
Büller, H. R., Agnelli, G., Hull, R. D., Hyers, T. M., Prins, M. H., & Raskob, G. E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.401s · Cited by 1,249
Levine, M., Gent, M., Hirsh, J., Leclerc, J., Anderson, D., Weitz, J., Ginsberg, J., Turpie, A. G., Demers, C., Kovacs, M., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341101 · Cited by 1,192
Self-citationHemorrhagic Complications of Anticoagulant Treatment
Levine, M. N., Raskob, G., Landefeld, S., & Kearon, C. (2001) · Chest · doi:10.1378/chest.119.1_suppl.108s · Cited by 1,134
Self-citationKoopman, M. M. W., Prandoni, P., Piovella, F., Ockelford, P. A., Brandjes, D. P. M., van der Meer, J., Gallus, A. S., Simonneau, G., Chesterman, C. H., Prins, M. H., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341102 · Cited by 1,111
Self-citationHeparin and Low-Molecular-Weight Heparin
Hirsh, J., & Raschke, R. (2004) · Chest · doi:10.1378/chest.126.3_suppl.188s · Cited by 971
Self-citationAllocation concealment in randomised trials: defending against deciphering
Schulz, K. F., & Grimes, D. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07750-4 · Cited by 923
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa035451 · Cited by 887
Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism
(1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371001 · Cited by 784
Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Self-citationRaschke, R. A., Reilly, B. M., Guidry, J. R., Fontana, J. R., & Srinivas, S. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-9-199311010-00002 · Cited by 743
Hull, R. D., Raskob, G. E., Hirsh, J., Jay, R. M., Leclerc, J. R., Geerts, W. H., Rosenbloom, D., Sackett, D. L., Anderson, C., Harrison, L., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610303151801 · Cited by 722
Self-citationNoninvasive Diagnosis of Deep Venous Thrombosis
Kearon, C., Julian, J. A., Math, M., Newman, T. E., & Ginsberg, J. S. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-8-199804150-00011 · Cited by 690
Self-citationBasu, D., Gallus, A., Hirsh, J., & Cade, J. (1972) · New England Journal of Medicine · doi:10.1056/nejm197208172870703 · Cited by 661
Self-citationFarrington, C. P., & Manning, G. (1990) · Statistics in Medicine · doi:10.1002/sim.4780091208 · Cited by 657
Büller, H. R., Davidson, B. L., Decousus, H., Gallus, A., Gent, M., Piovella, F., Prins, M. H., Raskob, G., Segers, A. E. M., Cariou, R., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-11-200406010-00007 · Cited by 617
Self-citationHemorrhagic Complications of Anticoagulant Treatment
Levine, M. N., Raskob, G., Beyth, R. J., Kearon, C., & Schulman, S. (2004) · Chest · doi:10.1378/chest.126.3_suppl.287s · Cited by 515
Self-citationHeparin for 5 Days as Compared with 10 Days in the Initial Treatment of Proximal Venous Thrombosis
Hull, R. D., Raskob, G. E., Rosenbloom, D., Panju, A. A., Brill-Edwards, P., Ginsberg, J. S., Hirsh, J., Martin, G. J., & Green, D. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005033221802 · Cited by 505
Self-citationThe Evaluation of Suspected Pulmonary Embolism
Fedullo, P. F., & Tapson, V. F. (2003) · New England Journal of Medicine · doi:10.1056/nejmcp035442 · Cited by 371
Fiessinger, J.-N., Huisman, M. V., Davidson, B. L., Bounameaux, H., Francis, C. W., Eriksson, H., Lundström, T., Berkowitz, S. D., Nyström, P., Thorsén, M., et al. (2005) · JAMA · doi:10.1001/jama.293.6.681 · Cited by 295
Self-citationHull, R. D. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.157.22.2562 · Cited by 261
Gould, M. K., Dembitzer, A. D., Sanders, G. D., & Garber, A. M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-10-199905180-00002 · Cited by 235
Customize your JAMA Network experience by selecting one or more topics from the list below. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.10.1077 · Cited by 127
O'Brien, B., Levine, M., Willan, A., Goeree, R., Haley, S., Blackhouse, G., & Gent, M. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.19.2298 · Cited by 121
Self-citationThe Importance of Initial Heparin Treatment on Long-term Clinical Outcomes of Antithrombotic Therapy
Hull, R. D. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.157.20.2317 · Cited by 115
Recurrent Venous Thrombosis and Heparin Therapy
Anand, S. S., Bates, S., Ginsberg, J. S., Levine, M., Buller, H. R., Prins, M. H., Haley, S., Kearon, C., Hirsh, J., & Gent, M. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.17.2029 · Cited by 88
Self-citationBates, S. M., Weitz, J. I., Johnston, M., Hirsh, J., & Ginsberg, J. S. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.3.385 · Cited by 84
Self-citationCouturaud, F., Julian, J. A., & Kearon, C. (2001) · PubMed · Cited by 61
Self-citationOptimal Dosing of Subcutaneous Unfractionated Heparin for the Treatment of Deep Vein Thrombosis
Kearon, C., Harrison, L., Crowther, M. A., & Ginsberg, J. S. (2000) · Thrombosis Research · doi:10.1016/s0049-3848(99)00189-9 · Cited by 13
Self-citation
Cited by
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Self-citationJaff, M. R., McMurtry, M. S., Archer, S. L., Cushman, M., Goldenberg, N., Goldhaber, S. Z., Jenkins, J. S., Kline, J. A., Michaels, A. D., Thistlethwaite, P., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318214914f · Cited by 2,229
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Self-citationPerioperative Management of Antithrombotic Therapy
Douketis, J. D., Spyropoulos, A. C., Spencer, F. A., Mayr, M., Jaffer, A. K., Eckman, M. H., Dunn, A. S., & Kunz, R. (2012) · Chest · doi:10.1378/chest.11-2298 · Cited by 1,641
Self-citation
Metadata
- Authors
- Kearon, C., Ginsberg, J. S., Julian, J. A., Douketis, J., Solymoss, S., Ockelford, P., Jackson, S., Turpie, A. G., MacKinnon, B., Hirsh, J., Gent, M., & Fixed-Dose Heparin (FIDO) Investigators, F. T.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2006-08-23
- Volume
- 296
- Issue
- 8
- Pages
- 935
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2166437990
- Cited by
- 259
- References
- 30
- FWCI
- 20.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.